摘要
近年来霍奇金淋巴瘤(HL)的研究取得了很大的进展。基础研究方面涉及全外显子测序等手段,研究显示HL通过多种基因机制实现免疫逃避;分期及预后方面涉及PET-CT引导的分期及预后指标以及部分生物学标志物,有助于更好地区分患者进行个体化治疗;治疗方面包括早期放化疗的选择、免疫检查点抑制剂、新型治疗方案的有效性和安全性研究以及多个大型临床试验结果更新等。文章就第60届美国血液学会(ASH)年会关于HL的研究进展进行介绍。
In recent years, research on Hodgkin lymphoma (HL) has made great progress. In basic research field, whole exon sequencing and other assay suggest that HL uses multiple genetic mechanisms to escape immune monitoring. In staging and prognosis aspects, PET-CT guided staging and prognostic indicators, as well as some biological indicators may help to stratify patients more exactly;treatment progress includes options of early chemotherapy and radiotherapy, along with efficacy and safety studies of checkpoint blockade, novel treatment regimens as well as updated data of clinical trials. The progress of HL reported in the 60th American Society of Hematology (ASH) Annual Meeting is introduced in this paper.
作者
张菁
范磊
李建勇
Zhang Jing;Fan Lei;Li Jianyong(Department of Hematology,the First Affiliated Hospital with Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,China)
出处
《白血病．淋巴瘤》
CAS
2019年第2期75-78,共4页
Journal of Leukemia & Lymphoma
基金
江苏省优秀青年基金(BK20160099)
江苏省六大高峰人才(2015-WSN-050).
关键词
霍奇金淋巴瘤
预后
治疗
Hodgkin lymphoma
Treatment
Prognosis
